Современные тенденции лечения пациентов с мочекаменной болезнью, осложненной хроническим калькулезным пиелонефритом

Abstract

Urolithiasis as a chronic pathological process having a ubiquitous, coupled with the need for emergency medical care, often resulting in permanent disability, not to lose over the years its importance and relevance. This calculous pyelonephritis is a leading pathology among the diseases of the urinary system, accompanied by disturbances of urodynamics and changes in renal parenchyma. In connection with the above stated it seems urgent comprehensive comparative approach to the study of metabolic disturbances in patients with urolithiasis in order to identify possible causes Lithogenesis and its complications, including pyelonephritis, for further development of optimal schemes of urolithiasis treatment and prevention of stone formation in these patients. The objective: to evaluate litholytic and antiinflammatory efficacy of Flavia® drug in patients with chronic calculous pyelonephritis. Patients and methods. The study involved 115 patients (74 men and 41 women aged from 23 to 76 years) who had been diagnosed with a stone in cup size from 5 to 10 mm, followed by chronic calculous pyelonephritis in a phase of latent inflammation. 60 patients who took Flavia® 1 caps. 2 times a day for 3 months. the main group (OG), 55 patients with the comparison group (HS) took herbal diuretics. Results. The results show that particularly relevant is the use of Flavia ® in patients with chronic calculous pyelonephritis, as the drug helps rid the patients of stones and relief of the inflammatory process, which in turn reduces the likelihood of recurrence of stone formation. Conclusion. The use of the drug has a pronounced Flavia® litholytic and litokinetichesky effect, as evidenced by not only the self-discharge of stones from the exhaust of patients, as well as significant reduction in the size of stones trapped in the cups. Anti-inflammatory and anti-microbial effectiveness Flavia® due to synergistic action of its active ingredients provides clinical efficacy in 96.7% of patients, thus expanding the scope of conservative treatment of urolithiasis complicated by chronic calculous pyelonephritis.